Edgewise Therapeutics, Inc. (EWTX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Edgewise Therapeutics, Inc. (EWTX) Bundle
Designed for accuracy, our (EWTX) DCF Calculator empowers you to evaluate Edgewise Therapeutics, Inc. valuation using up-to-date financial data and offers complete flexibility to modify all key parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -9.8 | -17.0 | -42.9 | -67.1 | -112.8 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .1 | .2 | .3 | .5 | 1.7 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -9.9 | -17.2 | -43.2 | -67.6 | -114.5 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 23.7 | 129.1 | 280.8 | 351.9 | 318.4 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .7 | 1.6 | 3.8 | 6.1 | 4.0 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.2 | -.2 | -.7 | -5.5 | -5.7 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -9.7 | -17.1 | -42.5 | -53.6 | -114.5 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -9.1 | -16.2 | -40.7 | -56.4 | -120.6 | -4.0 | .0 | .0 | .0 | .0 |
WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
PV UFCF | ||||||||||
SUM PV UFCF | -3.8 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -4 | |||||||||
Net Debt | -81 | |||||||||
Equity Value | 77 | |||||||||
Diluted Shares Outstanding, MM | 64 | |||||||||
Equity Value Per Share | 1.21 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real EWTX financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effects of your inputs on Edgewise Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive EWTX Data: Pre-loaded with Edgewise Therapeutics' historical performance metrics and future growth estimates.
- Tailorable Input Options: Modify parameters such as revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
- Adaptive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive Interface: Clean, organized design suitable for both industry experts and novices.
How It Works
- Step 1: Download the prebuilt Excel template with Edgewise Therapeutics' (EWTX) data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Edgewise Therapeutics' intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for Edgewise Therapeutics, Inc. (EWTX)?
- Accurate Data: Up-to-date Edgewise Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify crucial parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from scratch.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Edgewise Therapeutics stock (EWTX).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Edgewise Therapeutics (EWTX).
- Consultants: Deliver professional valuation insights on Edgewise Therapeutics (EWTX) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Edgewise Therapeutics (EWTX) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Edgewise Therapeutics (EWTX).
What the Template Contains
- Pre-Filled DCF Model: Edgewise Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Edgewise Therapeutics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.